Traditionally, BIO has been focused on bringing well-established biotech and pharma companies together. This year, the organizers wanted to shake things up abit and allow NIH/NSF funded SBIR companies, some of which have zero revenue, to showcase their business and have an opportunity to talk with investors and C-level execs about their work and vision for the future. This all occurred at the INNOVATION Zone in the Exhibitor Hall throughout the conference. There were more than 50 companies presenting with a focus on drug discovery, diagnostics, biofuels and many other platform technologies.
Image 1: Innovation Zone at @BioConvention Exhibitor Hall
There’s still time to meet with the companies. Below are some highlights to give you a taste of the cutting-edge technology that was presented:
PhylloTech developed a method to produce large amounts of protein from tobocca plants that is not only cost efficient but environmentally safe compared to traditional methods.
Privo Technologies developed a topical wafer for the treatment of oral cancer.
Humanetics developed an oral suspension pill that patients can take to protect them from the harmful effects of radiation therapy and diagnostic procedures.
Kiyatec developed a 3-D cell-based phenotypic models of cancer to allow for better testing of therapeutics targets.
Novasentis developed the world’s first digitally controlled catheter.
CytoVale developed a rapid label-free diagnostic platform to clinically validate hundreds of patient samples with 85% sensitivity and specificity.
Sharklet developed the world’s first texture designed to inhibit bacterial contamination. This is predominantly useful for tubing sets used in hospital settings where bacterial infections contribute to 10,000 deaths a year.
Phi Optics developed a label-free, non-invasive quantitative live cell imagining.
Image 2: Daniel Pfaff (left) and Danielle M. Stacy, PhD (right) present their company, PhylloTech, at #BIO2014 Innovation Zone.
It has been four decades since the initiation of President Nixon’s “War on Cancer”, but never have the signs for victory looked so encouraging. This is an exciting phase in cancer research, so much so that some in the field are even using the “c” word. Cure!
via Future of Cancer Therapeutics: BIO2014.
Consider a case where a patient has a disease with high mortality and no effective treatment available. A new experimental drug is now being tested in a clinical trial. However, this is a randomized clinical trial, which means that it will have a treatment group and a placebo group (that does not get the actual drug).
via Bioethics in Drug Development: BIO2014.